NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
4 trialsNCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT00898794 2013-08-07
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
National Cancer Institute (NCI)
Unknown